A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2002-05-31
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT00038415
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00038246
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2020-01-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT00038142
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00038194
- Locations
- 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT00038207
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Thalidomide for Multiple Myeloma
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00038233
- Locations
- 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00038181
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00038168
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Thalidomide-Dexamethasone for Multiple Myeloma
- First Posted Date
- 2002-05-29
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 83
- Registration Number
- NCT00038090
- Locations
- 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2002-05-27
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00038012
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath